Applying the Strategic Sacrifice Framework to RESEARCH PROPOSAL

Date: June 2026

Related work: DOI 10.5281/zenodo.19138511

Abstract

Contemporary biomedical research predominantly addresses Huntington’s disease (HD) by attempting to repair or protect damaged downstream neurons. This proposal argues that such an approach treats the symptom rather than the cause. Building on the Strategic Sacrifice Framework (Wijn, 2026), we propose that the deliberate partial inhibition of an upstream incidental process — specifically the production of mutant huntingtin protein (mHTT) — represents a more effective therapeutic strategy than downstream neuroprotection.

The HTT gene mutation produces a toxic byproduct (mHTT) that systematically destroys striatal neurons. Rather than repairing those neurons, the framework suggests strategically reducing mHTT production by 30–50%, preserving 70–90% of normal huntingtin function while eliminating the catastrophic downstream effect. This principle aligns with and provides theoretical grounding for emerging gene-silencing therapies (ASOs, RNAi, allele-specific silencing), while suggesting novel sacrifice points that remain underexplored.

This paper formalizes the framework, applies it systematically to the HD disease chain, identifies concrete research hypotheses, and proposes a roadmap for experimental validation.

1. Introduction

Huntington’s disease is a fatal, hereditary neurodegenerative disorder caused by a CAG trinucleotide repeat expansion in the HTT gene on chromosome 4. The resulting mutant huntingtin protein (mHTT) is toxic, forming aggregates that progressively destroy neurons — particularly in the striatum and cortex — producing a triad of motor, cognitive, and psychiatric symptoms. Onset typically occurs between ages 30 and 50, with death following 10–25 years later. No disease-modifying treatment currently exists.

The dominant research paradigm focuses on the downstream consequences: how to protect neurons from mHTT toxicity, how to clear aggregates, how to restore lost function. This is intuitive — it addresses what is visibly broken.

The Strategic Sacrifice Framework (Wijn, 2026) challenges this intuition. It proposes that in biological chains where an upstream process produces a toxic byproduct, the solution is not to repair the downstream damage but to partially inhibit the upstream source — accepting a small functional loss to prevent a catastrophic systemic failure. The framework formalizes a principle that nature employs constantly (fever, fasting, sleep, pain) but that biomedical science has been slow to adopt as a deliberate design strategy.

This paper applies that framework systematically to Huntington’s disease, deriving testable hypotheses and a concrete research agenda.

2. The Strategic Sacrifice Framework

2.1 Core Principle

The framework rests on a single insight: when a biological chain produces a toxic byproduct that destroys a downstream component, repairing the downstream component addresses only the symptom. The solution may lie in partially disrupting an incidental upstream step — reducing byproduct formation while preserving the chain’s primary function at 70–90% capacity.

This trade-off — a small functional sacrifice — may prevent catastrophic systemic failure.

2.2 Why This Is Missed

Three cognitive biases cause researchers to overlook this solution:

Fear of defects: When an inhibitor reduces a biological function, researchers interpret this as harm and abandon the approach — even when that reduction is the solution.
Symptom focus: Research concentrates on where the problem is visible (the failing downstream component) rather than where it originates (the upstream source of the toxic byproduct).
All-or-nothing thinking: The assumption that biological functions must operate at 100% ignores that many systems function adequately at 70–90% capacity.

2.3 The Strategic Checklist

To apply the framework to any disease, the following steps are followed:

Identify the disruptive substance or process causing the major problem.
Trace the source: which upstream chain produces it?
Analyze the chain: which steps are essential, which are incidental?
Test partial inhibition: can an incidental step be inhibited without losing primary function?
Weigh the trade-off: small defect (90% function) vs. large defect (disease/death)?

3. Huntington’s Disease: Mapping the Chain

3.1 The Disease Chain

Huntington’s disease can be understood as a biological chain in which an upstream process generates a toxic byproduct that destroys a downstream component:

Chain Step	What Happens	Classification
HTT gene (mutant)	CAG repeat expansion produces instruction for mHTT	Upstream source
Mutant mRNA	Transcribed from the HTT gene, including toxic exon 1 fragment	Incidental intermediate
Mutant huntingtin (mHTT)	Toxic protein that aggregates — this is Substance Z	The toxic byproduct
Striatal neurons (MSNs)	Progressively destroyed by mHTT aggregation	Downstream component (Chain B)
Motor / cognitive / psychiatric symptoms	Result of neuronal loss	Visible symptom

3.2 The Classical Error

The conventional research focus falls on the last two rows of the table: how to protect neurons, how to restore lost cognitive function, how to treat symptoms with tetrabenazine or antipsychotics. This is precisely the error the Strategic Sacrifice Framework predicts: we look at where the problem is visible (failing neurons) rather than where it originates (mHTT production).

3.3 Identifying the Sacrifice Points

Applying the framework’s checklist to Huntington’s disease yields three potential sacrifice points — upstream steps that are incidental rather than essential, where partial inhibition could reduce mHTT without eliminating huntingtin’s normal functions:

Sacrifice Point	Target	Mechanism	Estimated Function Retained
SP-1: mHTT transcription	Mutant HTT mRNA	Allele-specific ASOs / RNAi silencing	~70–80% normal HTT activity
SP-2: Exon 1 splicing	Toxic exon 1 fragment	Splice-switching oligonucleotides	~85–90% normal HTT activity
SP-3: mHTT aggregation step	Oligomerisation of mHTT	Aggregation inhibitors / chaperones	~90% normal HTT activity

Of these, SP-1 and SP-2 are the most upstream and therefore most consistent with the framework’s logic. SP-3 operates further downstream but still upstream of neuronal damage.

4. Alignment with Existing Research

Crucially, the Strategic Sacrifice Framework does not contradict current leading research — it provides a theoretical foundation that existing approaches have been applying intuitively without formal articulation.

Therapy	Mechanism	Framework Interpretation
Tominersen (ASO)	Reduces total huntingtin (both alleles) by ~50%	SP-1 sacrifice — accepted 50% reduction to halt mHTT toxicity
WVE-003 (allele-specific ASO)	Selectively silences mutant allele	SP-1 sacrifice — more precise, preserves normal HTT more fully
Branaplam (splicing modulator)	Reduces HTT mRNA via splicing alteration	SP-2 sacrifice — incidental splicing step partially inhibited
AMT-130 (RNAi gene therapy)	AAV5-delivered miRNA reduces mHTT in striatum	SP-1 sacrifice — localised, permanent upstream inhibition

The framework adds value by explaining why these approaches are theoretically sound despite appearing to ‘create a defect’ — the very resistance that has historically slowed their development. It also identifies which sacrifice points remain underexplored (notably SP-2, exon 1 splicing).

5. Novel Hypotheses Derived from the Framework

Hypothesis 1: The Optimal Sacrifice Threshold

The framework predicts that partial inhibition of mHTT — targeting 30–50% reduction — is sufficient to halt neurodegeneration while preserving enough normal huntingtin function to avoid iatrogenic harm. This threshold has not been systematically mapped. We hypothesize that a 40% reduction in mHTT levels will produce measurable neuroprotective effects in HD mouse models without significant loss of normal huntingtin-dependent neuronal function.

Hypothesis 2: Exon 1 Splicing as an Underexplored Sacrifice Point

The aberrant splicing of HTT exon 1 — producing a short, highly toxic fragment — represents a narrow, incidental step in the HTT expression chain. Splice-switching oligonucleotides that prevent exon 1 truncation may reduce toxicity while leaving full-length huntingtin expression largely intact. We hypothesize that SP-2 inhibition will produce a superior safety/efficacy profile compared to total HTT suppression.

Hypothesis 3: Combination Sacrifice Strategy

The framework suggests that multiple small sacrifices across a chain may be additive. Simultaneous partial inhibition at SP-1 (20% mHTT reduction) and SP-2 (20% exon 1 fragment reduction) may achieve the same neuroprotective effect as 40% inhibition at a single point, with less total disruption to normal huntingtin biology.

6. Proposed Research Agenda

Phase 1: In Vitro Threshold Mapping (Years 1–2)

Systematically map mHTT reduction thresholds (10%, 20%, 30%, 40%, 50%) against neuronal survival in HD iPSC-derived striatal neurons.
Quantify normal huntingtin function (vesicle transport, BDNF signalling) at each threshold.
Identify the sacrifice optimum: the point at which neuroprotection is maximal and normal function loss is minimal.

Phase 2: Exon 1 Splice-Switching Validation (Years 1–3)

Design and screen splice-switching oligonucleotides targeting HTT exon 1 truncation.
Compare SP-2 inhibition against SP-1 inhibition on toxicity and normal function metrics.
Characterize the exon 1 fragment as a distinct sacrifice point independent of full-length mHTT.

Phase 3: In Vivo Sacrifice Optimization (Years 2–4)

Test optimal sacrifice thresholds in R6/2 and zQ175 HD mouse models.
Measure motor function, striatal volume, aggregate load, and BDNF levels.
Test combination sacrifice (SP-1 + SP-2) against single-point strategies.

Phase 4: Biomarker Development (Years 3–5)

Identify blood-based biomarkers that reflect upstream mHTT production levels — enabling presymptomatic monitoring of sacrifice efficacy.
Link biomarker profiles to clinical outcome measures in existing HD cohorts (TRACK-HD, PREDICT-HD).

7. Broader Implications

If validated in Huntington’s disease, the Strategic Sacrifice Framework offers a generalizable methodology for neurodegenerative and other disease research. Diseases where an upstream process produces a toxic byproduct — rather than the downstream component being intrinsically defective — may all benefit from this approach.

Candidate conditions for framework application include:

Parkinson’s disease: alpha-synuclein overproduction as an upstream sacrifice target.
ALS: TDP-43 or FUS misprocessing as incidental upstream steps.
Alzheimer’s disease: amyloid precursor protein processing as a sacrifice point upstream of plaque formation.
Autoimmune diseases: specific cytokine production steps as sacrifice targets, preserving broader immune function.

The framework also has implications for drug development methodology: rather than screening for compounds that restore function, screens could be designed to identify strategic inhibitors of incidental upstream processes.

8. Conclusion

Huntington’s disease presents a clear instance of the pattern identified by the Strategic Sacrifice Framework: an upstream chain producing a toxic byproduct that destroys a downstream component. The conventional focus on downstream neuroprotection addresses the symptom. The framework directs attention to the source.

The most promising current therapies — ASOs, RNAi, splice modulators — are already applying this logic, often without theoretical articulation. The framework provides that articulation, explains why such approaches work despite appearing to ‘create defects’, identifies underexplored sacrifice points, and generates a concrete research agenda.

The question for Huntington’s research is not how to repair damaged neurons. The question is: which small upstream sacrifice will stop the damage from occurring?

“Perfection is not the goal. Balance is the goal. And balance sometimes requires strategic imperfection.” — Wijn, 2026

References

Wijn, M. (2026). Sacrifice in the Chain. Zenodo. https://doi.org/10.5281/zenodo.19138511

Tabrizi, S. J., et al. (2019). Targeting huntingtin expression in patients with Huntington’s disease. New England Journal of Medicine, 380(24), 2307–2316.

Kingwell, K. (2021). Double setback for ASO trials in Huntington disease. Nature Reviews Drug Discovery, 20(6), 412–413.

Bhatt, D. L., et al. (2022). Allele-selective suppression of mutant huntingtin: current approaches and future directions. Nature Reviews Neurology, 18, 521–536.

Wild, E. J., & Tabrizi, S. J. (2017). Therapies targeting DNA and RNA in Huntington’s disease. The Lancet Neurology, 16(10), 837–847.

Southwell, A. L., et al. (2018). Huntingtin suppression restores cognitive function in a mouse model of Huntington’s disease. Science Translational Medicine, 10(461).

Zeitler, B., et al. (2019). Allele-selective transcriptional repression of mutant HTT for the treatment of Huntington’s disease. Nature Medicine, 25, 1131–1142.

Acknowledgements

This research proposal was developed through a collaborative process between Mart Wijn (conceptual framework, systems-level reasoning, identification of research gaps) and Claude (Anthropic), an AI research tool that provided scientific literature grounding, biological detail, and structural elaboration. The theoretical framework, core insights, and research direction originate with the human author. Claude contributed knowledge synthesis and academic formalization.

The authors wish to acknowledge all HD patient communities and advocacy organizations whose lived experience makes this research urgent.